Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery  by Müller, Thomas et al.
at SciVerse ScienceDirect
Parkinsonism and Related Disorders 19 (2013) 501e507Contents lists availableParkinsonism and Related Disorders
journal homepage: www.elsevier .com/locate/parkreldisReviewEditor’s comment: Levodopa has now been available for the treatment of Parkinson’s disease for over 40 years and most neurologists are
very familiar with its use. Familiarity may, however, lead to a somewhat cavalier attitude toward the potential problems that can be
encountered with the use of levodopa. I suspect that very few neurologists, me included, have been acutely aware of the potential for
levodopa to produce peripheral neuropathy and of the frequency with which it does so. In this review, Müller and colleagues provide a
tremendously valuable service by bringing this to our attention and discussing approaches to treat and potentially avoid this surprisingly
common and sometimes dangerous adverse effect of what is still the most effective treatment available for Parkinson’s disease.
Ronald F. Pfeiffer, Editor-in-Chief Department of Neurology, University of Tennessee HSC, 875 Monroe Avenue, Memphis TN 38163, USAPeripheral neuropathy in Parkinson’s disease: Levodopa exposure and
implications for duodenal delivery
[Universally Available]
Thomas Müller a,*, Teus van Laar b, David R. Cornblath c, Per Odin d, Fabian Klostermann e,
Francisco J. Grandas f, Georg Ebersbach g, Peter P. Urban h, Francesc Valldeoriola i, Angelo Antonini j
aDepartment of Neurology, St. Joseph Krankenhaus Berlin-Weißensee, Gartenstr. 1, 13088 Berlin, Germany
bDepartment of Neurology, University Medical Center Groningen, Groningen, The Netherlands
cDepartment of Neurology, The John Hopkins University School of Medicine, Baltimore, MD, USA
dDepartment of Neurology, Klinikum Bremerhaven, Bremerhaven, Germany
eDepartment of Neurology, Charité-University Medicine Berlin, Berlin, Germany
fMovement Disorders Research Unit, Hospital General Universitario Gregorio Marañόn, Madrid, Spain
gMovement Disorders Clinic, Klinikum Beelitz, Beelitz, Germany
hDepartment of Neurology, Asklepios Klinik Barmbek, Hamburg, Germany
iMovement Disorders Unit, University of Barcelona, Hospital Clinic, Barcelona, Spain
j Parkinson Unit, IRCCS San Camillo, Venice, Italya r t i c l e i n f o
Article history:
Received 4 September 2012
Received in revised form
12 February 2013
Accepted 13 February 2013
Keywords:
Peripheral neuropathy
Parkinson’s disease
Levodopa/carbidopa intestinal gel
Homocysteine
Vitamin B* Corresponding author. Tel.: þ49 30 92790223.
E-mail addresses: th.mueller@alexius.de, thomas.m
1353-8020 2013 Elsevier Ltd.
http://dx.doi.org/10.1016/j.parkreldis.2013.02.006
Open access under CC BYa b s t r a c t
In advanced Parkinson’s disease (PD) patients, continuous intra-duodenal infusion of levodopa/carbidopa
intestinal gel (LCIG) is an established approach in the management of motor complications that cannot
be further improved by conventional oral therapy. In general, tolerability of LCIG has resembled that of
oral dopaminergic therapy; however, cases of symptomatic peripheral neuropathy (PN), sometimes se-
vere, have been reported in patients receiving LCIG. Cases are generally a sensorimotor polyneuropathy
with both subacute and chronic onsets, often associated with vitamin B12 and/or B6 deﬁciency. Rare
cases clinically resemble Guillain-Barré syndrome. In the absence of prospectively collected data on
possible associations between LCIG and PN, it is prudent to explore potential mechanisms that may
explain a possible relationship. The PN may be linked to use of high-dose levodopa, promoting high
levels of homocysteine and methylmalonic acid or reduced absorption of vitamins essential for homo-
cysteine metabolism. Cases of LCIG-associated PN often have responded to vitamin supplementation
without need for LCIG cessation, although LCIG cessation is sometimes necessary. It may be advisable to
monitor vitamin B12/B6 status before and after patients start LCIG and be vigilant for signs of PN. Pro-
spective, large-scale, long-term studies are needed to clarify whether vitamin supplementation and
routine use of a catechol-O-methyltransferase inhibitor may help prevent PN in LCIG recipients and
whether these measures should be routine practice in patients with PD on high-dose oral levodopa.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.ueller@ruhr-uni-bochum.de (T. Müller).
-NC-ND license.
T. Müller et al. / Parkinsonism and Related Disorders 19 (2013) 501e5075021. Introduction incidence cannot be estimated from these case reports. PN also has
been reported in long-term recipients of oral levodopa, in whomHalf a century after its introduction, levodopa continues to be
the most effective pharmacotherapeutic option for ameliorating
the motor symptoms of Parkinson’s disease (PD) [1,2]. In advanced
PD with severe complications that cannot be controlled by oral or
transdermal adjuncts to oral levodopa, invasive pharmacologic and
surgical options have included the continuous subcutaneous infu-
sion of the dopamine agonist apomorphine [3,4] and deep brain
stimulation (DBS) of the bilateral subthalamic nucleus or internal
globus pallidus [5e7]. Continuous intra-duodenal infusion of
levodopa/carbidopa intestinal gel (LCIG), a carboxymethylcellulose
(carmellose sodium) gel suspension of levodopa plus the dopa-
decarboxylase inhibitor (DDI) carbidopa [8], is another recent
continuous drug delivery approach for advanced PD.
Tolerability resembles that of oral dopaminergic therapy [9e12],
except for surgical and delivery-system events (e.g. tube disloca-
tion) [10,11,13]. LCIG uses a carboxymethylcellulose/water vehicle,
an agent that is frequently used as a food thickener [14]. Cases of
symptomatic peripheral neuropathy (PN)dsome severedhave
been reported in LCIG recipients [12,15,16]; however, overallTable 1
PN and related ﬁndings in PD case series and other studies.
Authors/year Type of study (patient groups) PN prevalence
Taly
et al., 1992 [19]
Case series (29 juvenile-PD patients) Abnormal sensory conduc
31%; abnormal motor con
in 14%
Khan
et al., 2003 [20]
Genetic case series (24 patients with
parkin mutation)
Symptomatic PN in 1 levo
naïve patient
Müller
et al., 2004 [21]
Pharmacokinetic/pharmacodynamic
(31 patients on oral levodopa/DDI;
27 non-PD controls)
e
Ohsawa
et al., 2005 [22]
Caseecontrol study (9 PD patients
with parkin mutation; 8 idiopathic
PD patients)
Sensory symptoms in 2 p
mutation patients and 2 i
PD patients
Nolano
et al., 2008 [23]
Caseecontrol study (18 PD patients;
30 healthy controls)
Paresthesia or “burning fe
in 33%
Toth et al., 2008 [17] Caseecontrol study (34 PD patients
with symptomatic idiopathic PN;
22 PD-only patients; 258 non-PD
PN patients)
All cases (by study design
Chovancova
et al., 2009 [24]
Case series (23 PD patients) PN signs in 43%
Capuano
et al., 2010 [12]
ADR-database search PN in 7 patients on LCIG
(among an undescribed n
of ADR reports)
Gondim
et al., 2010 [25]
Case series (10 PD patients with PN) All subjects (by study des
Montastruc
et al., 2010 [26]
ADR-database search PN in 3 patients on oral l
(among 174,341 ADR rep
Toth et al., 2010 [18] Caseecontrol study (58 PD patients;
58 community controls)
PN signs in 55% of patien
9% of controls; symptoma
in 41% of patients and 5%
controls
Nolano
et al., 2011 [27]
Case series (21 PD patients) e
Rajabally
et al., 2011 [28]
Cross-sectional, caseecontrol study
(37 PD patients and 37 controls)
PN in 38% of PD patients
of controls
ADR ¼ adverse drug reaction; DDI ¼ dopa-decarboxylase inhibitor; GBS ¼ Guillain-Barré
PD ¼ Parkinson’s disease; PN ¼ peripheral neuropathy.signs or symptoms develop in as many as 12% [17,18].
This review describes the reported cases, surveys the mecha-
nisms hypothesized for subacute and chronic cases and offers
interim suggestions for management and possible prevention.
2. Methods
A thorough and systematic literature search of PubMed used multiple combi-
nations of the following search terms: “advanced Parkinson”, “advanced Parkinson’s
disease”, “levodopa”, “duodenal levodopa infusion”, “levodopa/carbidopa intestinal
gel”, “LCIG”, “polyneuropathy”, “peripheral neuropathy”, “neuropathy”, “vitamin B”
and “homocysteine”. We subsequently reviewed abstracts for relevance and then
searched the reference lists of appropriate articles to obtain any other pertinent
references or search terms thatwere not captured during the original PubMed search.
3. Results: review of the literature
3.1. PN in PD in the absence of LCIG therapy
PN occurs in patients with PD (Table 1). PN was identiﬁed
clinically and by electromyography (EMG) in 10 (43%) of 23 patientsClinical ﬁndings Interventions/outcomes
tion in
duction
e e
dopa- Axonal PN “Dramatically” responsive
to trihexyphenidyl initially;
moderate motor response
at 7 years
Sural-nerve action potentials were
lower in PD patients than in controls
(in association with homocysteine
elevation), but conduction velocity
was no different
e
arkin-
diopathic
Reduced sural-nerve action-potential
amplitude in 8 parkin-mutation patients
but not in idiopathic PD patients
e
et” Across the PD group, abnormal sensation
thresholds plus epidermal nerve-ﬁber
and Meissner corpuscle loss
e
) Elevated homocysteine or MMA Intra-muscular B12 led to
PN stabilization at 24 and
36 months
e e
umber
Neuropathy in 2, polyneuropathy in 3,
GBS in 2
LCIG cessation or
interruption led mostly
to at least gradual
improvement
ign) Primarily axonal PN but demyelinating
features in 2 patients; low B12 and/or
elevated homocysteine in 6 patients;
all patients on oral levodopa
Intra-muscular B12 and
oral folate led to PN
improvement (time frame
not speciﬁed)
evodopa
orts)
PN was reported as ADR, but levodopa
role was excluded or doubtful
e
ts and
tic PN
of
Predominantly axonal PN, associated
with levodopa exposure; elevated
homocysteine and MMA
e
Meissner corpuscle loss found only in
levodopa recipients
e
and 8% Associated B12 deﬁciency in 50% of
patients with PD þ PN and 14% of
non-PD controls; signiﬁcant correlation
among cumulative levodopa exposure,
B12 level and PD duration in patients
with PD þ PN
e
syndrome; LCIG ¼ levodopa/carbidopa intestinal gel; MMA ¼ methylmalonic acid;
T. Müller et al. / Parkinsonism and Related Disorders 19 (2013) 501e507 503with PD [24]. Rajabally et al. [28] studied 37 patients with PD and 37
controls; PN was diagnosed in 14 (38%) patients with PD and 3 (8%)
controls. When the 14 patients with PD and PN were compared
with 28 age- and gender-matched controls with PN but not PD, B12
deﬁciency was found to be the sole cause in 7 (50%) patients with
PD versus 4 (14%) controls. In the patients with PN, B12 levels were
signiﬁcantly lower in patients with PD than without PD (286.8
versus 413.2 ng/L). In the total cohort of patients with PD, there
were no correlations between cumulative levodopa exposure,
vitamin B12 levels, neuropathy status or Utah Early Neuropathy
Scale scores, although signiﬁcant correlations existed in patients
with PD and PN between cumulative levodopa exposure and both
disease duration and vitamin B12 levels.
In a prospective, unblinded caseecontrol study of PN in which
500 patients with PDwere screened for PN and compared with 258
patients with idiopathic PN but not PD [17], “idiopathic” PN was
diagnosed in 34 (7%) patients with PD. Of these 34 patients with
idiopathic PN, 32 (94%) had abnormal serum levels of B12, homo-
cysteine and/or methylmalonic acid (MMA). In comparison, 26
(10%) patients with idiopathic PN but not PD had abnormal serum
levels of B12, homocysteine and/or MMA. For B12 deﬁciency alone
(deﬁned by levels 250 pg/mL), the percentage was 44% versus
10%, respectively. Among the 22 patients with PD with neuro-
muscular conditions other than PN, none were B12 deﬁcient. In the
PD-plus-PN group, cumulative levodopa exposure correlated with
PN severity. The mean levodopa exposure and mean PD duration
were signiﬁcantly greater in the PD-plus-PN group, compared with
the PD-without-PN group. Exposure to other PD drugs, including
catechol-O-methyltransferase (COMT) inhibitors, was similar be-
tween groups. Intra-muscular B12 for 1e2 years (at 1000 mg once
per month) led to PN stabilization accompanied by normalization
of B12 deﬁciency and statistically signiﬁcant decreases of
homocysteine and MMA elevation in all patient groups.
In another caseecontrol study [18], PN was diagnosed in 32
(55%) of 58 randomly selected patients from a movement disorder
clinic, compared with 5 (9%) of 58 age- and sex-matched controls.
Of note, the mean age of patients with PD and PN exceeded that of
patients with PD without PN by approximately 9 years, leading to
possible bias by inclusion of relatively young patients and not
severely ill patients with long durations of exposure.
Teodoro et al. [29] reviewed published clinical trials of PD drugs
versus placebo in search of a possible signal linking PNwith the use
of levodopa or other PD pharmacotherapy. In 79 studies encom-
passing 10,620 recipients of active agents and 6710 recipients of
placebo (with a total of 12,543 patients exposed to levodopa), no
subjects experienced neuropathy as a reported adverse event.
Frequencies of event types “suggestive of neuropathy” showed no
signiﬁcant differences between active treatment and placebo in any
trial. Only 7 of the trials followed subjects for more than a year;
thus, duration of exposure and route of administration were not
adequately studied as potential factors in PN development, and
none of the trials assessed LCIG.
Genetic studies suggest that the prevalence of asymptomatic PN
in PD might be high in patients with parkin (PARK2) mutations
[19,20,22]. In a study of 29 patients with juvenile PD [19], 9 (31%)
patients had abnormal conduction ﬁndings in the sural nerve and 4
(14%) had abnormal ﬁndings in the peroneal nerve, independent of
individual PD duration, severity, pharmacotherapy, and age at PD
onset. In a subsequent study of 24 patients with identiﬁed parkin
mutations [20], symptomatic PN accompanied by autonomic
dysfunction was present in 1 (4%) patient.
In a study of 9 patients with PD with parkinmutation (PD onset
at ages of 20e52 years) and 8 patients with idiopathic PD (onset at
ages of 47e59 years) [22], a strong association was seen between
asymptomatic axonal PN and presence of parkin mutation. Inthe parkin-mutation group, 2 (22%) patients had subjective sen-
sory symptoms and 8 (89%) had objective evidence of sensory loss
or abnormal nerve conductions. In the idiopathic PD group, 2
(25%) patients reported foot dysesthesia, but no patients had
abnormal sural-nerve action potentials. The authors concluded
that sensory axonal PN might be sufﬁciently common in PD
patients with parkin mutation to serve as a distinguishing diag-
nostic indicator.
3.2. LCIG-associated PN
Reported cases of PN in recipients of LCIG therapy (Table 2) do
not reﬂect a single type of polyneuropathy. Two general proﬁles of
PN have been observed in LCIG patients: a less severe sensory
axonal subtype that is slowly progressive, and a less common
subtype that clinically resembles Guillain-Barré syndrome and
causes severe deﬁcits. Disease onset ranges from a few weeks [35]
to up to 3 years after initiation of LCIG [31]. Nerve conduction
studies show both axonal and demyelinating features [30,38]. In
most cases, there are vitamin B12 deﬁciencies [12,15,33,35,36] and
an increase in serum homocysteine levels. Vitamin B6 and folate
(B9) deﬁciencies also have been reported [33,35,36]. Symptoms
generally improve after discontinuation or dose modiﬁcation of
LCIG, B-vitamin supplementation, or both [12,15,16,33,35,36].
4. Hypothesized levodopa-related mechanisms
Chronic levodopa therapy is associated with homocysteine
elevation, caused by levodopa serving as a co-enzyme in the
breakdown of methionine [39]. Homocysteine levels in recipients
of long-term levodopa therapy have been reported to be elevated
by 30e80%, compared with levels in levodopa-naïve patients with
PD or healthy controls [40e48]. Hyperhomocysteinemia is hy-
pothesized to affect neurologic function via oxidative stress, mito-
chondrial dysfunction, inﬂammation, loss of DNA repair systems,
and glutamatergic excitotoxicity [17,18,49,50]. A study of 31 pa-
tients with PD on long-term oral levodopa/DDI found a signiﬁcant
difference in sural action-potential amplitude between patients
with homocysteine levels exceeding 15 mmol/L and patients with
normal levels [30].
Co-administration of levodopa and DDI increases levodopa
metabolism by a pathway (Fig. 1) whereby COMT mediates its
conversion by methylation into 3-O-methyldopa [51]. COMT re-
quires S-adenosylmethionine (SAM) as the methyl-group donor,
which converts into S-adenosylhomocysteine, a short-lived inter-
mediary that is cleaved almost immediately into homocysteine.
Homocysteine is metabolized by its reversible re-methylation to
methionine or by an irreversible transsulfuration that converts it to
cysteine, a sulfhydryl-containing amino acid with chemical prop-
erties similar to those of homocysteine (Fig. 1) [52,53]. Total plasma
homocysteine accumulation can reﬂect an altered intra-cellular
scenario that encourages reduced ability for methyl-group trans-
fers [54].
Chronic O-methylation of levodopa may hypothetically weaken
the capacity for other de-toxiﬁcation processes that add methyl
groups to endogenous and exogenous toxins [55]. As a result,
vulnerability to toxins and pesticides increases.
In vitro, cysteine has cytotoxic effects against neurons and
vascular endothelial cells, mediated partly by its formation of an
adduct with nitric oxide [52]. In a study of 30 patients with PD,
blood was sampled at 1 h after levodopa/DDI intake and showed
increased levels of plasma cysteine in only the 18 patients with
baseline plasma homocysteine levels exceeding 15 mmol/L [56].
This group’s daily and morning levodopa/DDI intake also was
signiﬁcantly higher than that of the other patients with PD.
Table 2
Published and presented descriptions of PN in LCIG recipients.
Authors/year Type of study Number of PN cases Case presentation Interventions/outcomes
Antonini et al., 2007 [16] 12-month, open-label
trial
1 patient on LCIG
(among 9 such
patients)
Acute, GBS-like PN at 7 months LCIG was discontinued; plasmapheresis
was performed; had “some beneﬁt”
(time frame not speciﬁed)
Manca et al., 2009 [15] Individual case report 1 patient on LCIG Severe axonal PN at 4 months; elevated
homocysteine and MMA; low-normal B12
LCIG was discontinued; B12
supplementation led to improvement
in limb strength at 2 weeks and ability
to walk with a cane at 3 months
Carrillo F. unpublished data
(described and cited in
Santos-García et al. [30])a
Individual case report 1 patient on LCIG Acute, severe axonal PN at 5 months;
“borderline” B12; elevated urinary MMA
LCIG discontinued and replaced with
oral levodopa; parenteral B12
supplementation
Gusmaroli et al., 2010 [31] Individual case report 1 patient on LCIG Axonal PN at 3 years; low 25-OH
vitamin D
LCIG was continued; vitamin D
supplementation and hypercaloric
diet led to improvement (time frame
not speciﬁed)
Palasí et al., 2010 [32] Individual case report 1 patient on LCIG Small-ﬁber autonomic-sensitive PN at 15
months; normal B12 and folate levels;
elevated MMA
B12 and folate supplementation;
PN improved
Urban et al., 2010 [33] Individual case reports 2 patients on LCIG Subacute axonal PN at 13 months;
elevated homocysteine; low-normal B12;
low B6; high-normal or elevated MMA
LCIG was continued; parenteral B12/B6
supplementation led to stabilization at
10 months
Valldeoriola et al., 2010 [34] Individual case reports 2 patients on LCIG Axonal PN at 2 and 8 months; low B12 B12 and folate supplementation; PN
did not worsen
Klostermann et al., 2012 [35] Case series 2 patients on LCIG
(among 20 such
patients)
Severe axonal PN at “a few weeks”;
elevated homocysteine; low-normal B12;
low B6 and folate
LCIG was continued; B12, B6 and folate
supplementation led to motor
(but not sensory) improvement over
“several” months
Meppelink et al., 2011 [36] 6-month, open-label
trial
2 patients on LCIG
(among 15 such
patients)
Axonal PN (with time to onset not
described); borderline B12
LCIG dose reduction and B12
supplementation led to PN improvement
(time frame not speciﬁed)
Santos-García et al., 2011 [37] Individual case report 1 patient on LCIG Axonal PN at 6 months; reduced serum
B12 and folate levels
LCIG dose reduction; folate and B12
supplementation; later presented with
slight paresthesia in both feet without
pain but normal folate and B12 levels
25-OH ¼ 25-hydroxy vitamin D; GBS ¼ Guillain-Barré syndrome; LCIG ¼ levodopa/carbidopa intestinal gel; MMA ¼ methylmalonic acid; PN ¼ peripheral neuropathy.
a This unpublished case was presented by Fátima Carrillo as a brief talk in the LVII Reunión Anual de la Sociedad Española de Neurología in Barcelona, Spain.
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homocysteinemia is clinically beneﬁcial [40]. Nevertheless, to
prevent or reverse hyperhomocysteinemia in patients with PD,
physicians should consider vitamin B supplementation and
adjustment of a patient’s levodopa adjuncts.
In theory, the demands of levodopa metabolism on the body’s
stores of B vitamins might lead to B vitamin depletion [35].
Malnutrition and/or weight loss might be an exacerbating factor
[57], and in recipients of LCIG, intestinal vitamin malabsorption
might be another factor [58].
B12 and folate support the metabolism (re-methylation) of
homocysteine to methionine, and B6 supports the conversion of
homocysteine to cysteine. Thus, supplementation of B12, folate,
and/or B6 will reduce homocysteine levels [53].
5. Discussion
Evidence from caseecontrol studies suggests that PN in PD is
associated with a cumulative dose of levodopa during treatment, as
well as vitamin B12, B6, and/or folate deﬁciencies, and with
dysfunction of homocysteine metabolism [17,25,28]. These ﬁnd-
ings, however, have yet to be corroborated in clinical trials. A ge-
netic cause may also play a role, supported by studies indicating
that idiopathic axonal PN in PD might be associated with parkin
gene mutation [19,22]. Although the literature on PN in patients
receiving LCIG is currently limited, an association with vitamin B
deﬁciency also has been reported [15,31e33,35e37]. In both oral
levodopa and LCIG settings, the PN has been variable; onsets have
ranged from acutedlike Guillain-Barré syndromedto chronic, as is
more typical of vitamin deﬁciencies. The PN has usually been
sensory and motor, but physiology has suggested both an axonaland a demyelinating component. Vitamin B12, B6, and/or folate
deﬁciency is the most common feature, and clinical improvement
frequently follows multi-vitamin replacement.
The available data have raised questions concerning whether
and towhat extent PN is an inherent feature of PD, whether PN is an
iatrogenic outcome of intensive levodopa exposure and/or an effect
speciﬁc to levodopa as a gel delivered directly to the small intestine
(LCIG), how PN might best be prevented and managed when it
occurs, and whether LCIG plays a role in vitamin B malabsorption,
leading to development of PN.
In clinical practice, when a patient is being evaluated for LCIG
therapy and in order to help gauge pre-disposing risk factors for PN,
we recommend that special attention be devoted to body mass
index, nutritional status, vitamin supplement usage, medication
usage (for cytochrome P450 interaction), and conditions that could
lead to gastrointestinal malabsorption. A detailed neurologic ex-
amination as well as nerve conduction studies and a needle EMG
should be conducted to detect a possible pre-existing neuropathy.
Baseline laboratory assessments might include plasma values
for vitamins B6 and B12, folic acid, homocysteine, and MMA with
evaluation of current use of vitamin B supplements, levodopa
dosage, and levodopa equivalent dosages.
In the presence of laboratory abnormalities, decisions about
whether and when to start LCIG should be made clinically. How-
ever, patients with acute PN symptoms or severe chronic PN, as
determined by the above workup, should not start treatment with
LCIG. Patient-speciﬁc factors could include availability and efﬁcacy
of alternative treatment options, co-morbidities, and patient pref-
erences. Methylenetetrahydrofolate reductase (MTHFR) genotyp-
ingmay be considered; however, its utility in clinical practice is still
subject to debate.
Dopamine
3-OMDCH3
ATP
 S-adenosyl-
methionine
 S-adenosyl-
homocysteine
Methionine
Homocysteine
Cysteine
CH3
H2O
MMA
THF
Methylene-
THF
Methyl-
THF
One-
carbon
folate
pool
Levodopa
Fig. 1. Facets of levodopa and homocysteine metabolism hypothesized to be relevant
to peripheral neuropathy in patients with Parkinson’s disease. Conversion of levodopa
into 3-O-methyldopa (3-OMD) depletes methyl-group (CH3) reserves and leads to
homocysteine production. Subsequent homocysteine re-methylation (into methio-
nine) requires vitamin B12 (cobalamin) as a co-factor and obtains its CH3 from the one-
carbon folate pool. Involvement of methylenetetrahydrofolate (methylene-THF) in
supplying the CH3 makes polymorphism in methylene-THF reductase an important
determinant of plasma homocysteine level. Homocysteine trans-sulfuration (into
cysteine) requires vitamin B6 (pyridoxine). A pathway leading to methylmalonic acid
(MMA) makes MMA as well as homocysteine a marker of functional vitamin B12
deﬁciency. ATP ¼ adenosine triphosphate.
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dopa), the potential beneﬁt of vitamin supplementation should be
evaluated. Vitamin status can change rapidly after levodopa ther-
apy starts and PN has been seen within weeks to months of levo-
dopa initiation. The evaluation of vitamins B6 and B12, folate, and
homocysteine monthly for the ﬁrst 6 months, and then every 6
months thereafter, should be considered [28], with patients
receiving vitamin supplementation as needed, based on deter-
mined deﬁciencies.
For patients with vitamin deﬁciency associated with homocys-
teine elevation, oral folate and vitamin B6 supplements can be
given daily and parenteral vitamin B12 supplementation can be
administered monthly. No standardized recommendations are
available for B12 supplementation and regimens vary, although
daily or weekly administration is sometimes suggested for up to 8
weeks before establishing the monthly regimen [59e61]. High-
dose oral vitamin B12 (2000 mg/day tapered to 1000 mg/day and
then 1000 mg/day weekly segueing to monthly) also has been rec-
ommended [61,62].
Because levodopa metabolism is inﬂuenced by the enzymatic ac-
tivities of DDI and COMT inhibitors, administration of levodopa plus
an inhibitor of either enzyme might reduce hyperhomocysteinemia[47,63], although ﬁndings regarding the effect of levodopa plus
entacapone on homocysteine levels have been inconsistent [18].
COMT inhibitors also may provide an opportunity to reduce the LCIG
dose [64] and, thus, reduceapresumablydose-dependentpotential of
levodopa to induce PN.
Visiting a neurologic center every 3e4 months (rather than only
if complications occur) should be routine practice, as it is already
for patients with advanced PD.
In patients with chronic PN, the decision to continue or stop
LCIG should depend on the clinical picture of the individual patient.
If deﬁcient or marginal laboratory values are determined, vitamin
supplementation is recommended.
In patients with acute PN, LCIG should be stopped and oral
levodopa should be re-instituted, if possible at a lower levodopa
equivalent dose/day. Speciﬁc conditions, such as vitamin deﬁciency
and hyperhomocysteinemia, should be treated, and further diag-
nostic evaluation and treatment should follow local standards for
the treatment of PN.
The development of a structured assessment that includes a
standardized questionnaire and standardized batteries of clinical
neurophysiologic and laboratory tests would facilitate the collec-
tion and analysis of data in both clinical practice and research.
Ongoing LCIG studies could incorporate such an assessment and
possible PN symptoms and precursors could be reported as adverse
events of special interest.
In addition to epidemiologic analyzes of existing databases,
prospective studies should assess the incidence of PN and seek its
causes in populations of patients with PD, related to vitamin levels,
homocysteine metabolism, genetics, and inﬂuence of cumulative
levodopa dosages.
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